Adipose-derived stem cell therapeutics

N/A

Report date: 2023/01/12 15:30:08

Base Information

Drug NameAdipose-derived stem cell therapeutics
Drug Alias NameATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionGrowth stimulantsCell replacementsTissue replacements +[4] 
TargetsCytokines
Therapy Area/IndicationsPost-Acute COVID-19 SyndromePost-Concussion SyndromeMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesCayman Islands
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmerican Cryostem Corporation
China Registration ClassN/A

Develop Information

Active CompaniesAmerican Cryostem Corporation
Inactive CompaniesN/A
Active IndicationsPost-Acute COVID-19 SyndromePost-Concussion Syndrome
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A